v3.26.1
License Revenues - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Sep. 12, 2024
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2022
Dec. 31, 2025
Oct. 01, 2024
Sep. 11, 2023
Oct. 31, 2021
Sep. 30, 2020
Related Party Transaction [Line Items]                  
Common stock, Shares issued   54,582,749     43,223,090   11,021,248    
Reverse stock split   Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.              
Accounts receivable   $ 1,230,000     $ 52,000        
Deferred revenue current   1,485,000     1,188,000        
Deferred revenue noncurrent   6,322,000     5,770,000        
Zenas BioPharma Inc [Member]                  
Related Party Transaction [Line Items]                  
Reimbursement of development costs       $ 1,100,000          
Common stock, Shares issued                 156,848
Zenas BioPharma Inc [Member] | IPO [Member]                  
Related Party Transaction [Line Items]                  
Price per share $ 17                
Reverse stock split 1-for-8.6831                
Fair value of the investment   400,000     700,000        
Zenas BioPharma Inc [Member] | Milestone [Member]                  
Related Party Transaction [Line Items]                  
Development milestones       11,000,000          
Zenas BioPharma Inc [Member] | Royalty [Member]                  
Related Party Transaction [Line Items]                  
License revenue - related party   0              
Zenas BioPharma Inc [Member] | Upfront Payment [Member]                  
Related Party Transaction [Line Items]                  
Upfront payments       $ 1,000,000       $ 1,000,000  
Tenacia Biotechnology (Hong Kong) Co., Limited [Member]                  
Related Party Transaction [Line Items]                  
License revenue - related party   500,000 $ 1,200,000            
Accounts receivable   1,200,000     52,000        
Unbilled receivable   83,000     50,000        
Deferred revenue current   1,500,000     1,200,000        
Deferred revenue noncurrent   6,300,000     $ 5,800,000        
Tenacia Biotechnology (Hong Kong) Co., Limited [Member] | Milestone [Member]                  
Related Party Transaction [Line Items]                  
Development milestones   15,000,000       $ 15,000,000      
Revenue related to milestones   $ 7,000,000              
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]   License revenue - related party              
Tenacia Biotechnology (Hong Kong) Co., Limited [Member] | Upfront Payment [Member]                  
Related Party Transaction [Line Items]                  
Upfront payments           $ 2,500,000